BACKGROUND: Differential responses to tamoxifen may be due to inter-patient variability in tamoxifen metabolism into pharmacologically active Z-endoxifen. Z-endoxifen administration was anticipated to bypass these variations, increasing active drug levels, and potentially benefitting patients responding sub-optimally to tamoxifen. MATERIALS AND METHODS: Patients with treatment-refractory gynecologic malignancies, desmoid tumors, or hormone receptor-positive solid tumors took oral Z-endoxifen daily with a 3+3 phase 1 dose escalation format over 8 dose levels (DLs). Safety, pharmacokinetics/pharmacodynamics, and clinical outcomes were evaluated. RESULTS: Thirty-four of 40 patients were evaluable. No maximum tolerated dose was established. DL8, 360 mg/day, was used for the expansion phase and is higher than doses administered in any previous study; it also yielded higher plasma Z-endoxifen concentrations. Three patients had partial responses and 8 had prolonged stable disease (≥ 6 cycles); 44.4% (8/18) of patients at dose levels 6-8 achieved one of these outcomes. Six patients who progressed after tamoxifen therapy experienced partial response or stable disease for ≥ 6 cycles with Z-endoxifen; one with desmoid tumor remains on study after 62 cycles (nearly 5 years). CONCLUSIONS: Evidence of antitumor activity and prolonged stable disease are achieved with Z-endoxifen despite prior tamoxifen therapy, supporting further study of Z-endoxifen, particularly in patients with desmoid tumors. Copyright:
BACKGROUND: Differential responses to tamoxifen may be due to inter-patient variability in tamoxifen metabolism into pharmacologically active Z-endoxifen. Z-endoxifen administration was anticipated to bypass these variations, increasing active drug levels, and potentially benefitting patients responding sub-optimally to tamoxifen. MATERIALS AND METHODS: Patients with treatment-refractory gynecologic malignancies, desmoid tumors, or hormone receptor-positive solid tumors took oral Z-endoxifen daily with a 3+3 phase 1 dose escalation format over 8 dose levels (DLs). Safety, pharmacokinetics/pharmacodynamics, and clinical outcomes were evaluated. RESULTS: Thirty-four of 40 patients were evaluable. No maximum tolerated dose was established. DL8, 360 mg/day, was used for the expansion phase and is higher than doses administered in any previous study; it also yielded higher plasma Z-endoxifen concentrations. Three patients had partial responses and 8 had prolonged stable disease (≥ 6 cycles); 44.4% (8/18) of patients at dose levels 6-8 achieved one of these outcomes. Six patients who progressed after tamoxifen therapy experienced partial response or stable disease for ≥ 6 cycles with Z-endoxifen; one with desmoid tumor remains on study after 62 cycles (nearly 5 years). CONCLUSIONS: Evidence of antitumor activity and prolonged stable disease are achieved with Z-endoxifen despite prior tamoxifen therapy, supporting further study of Z-endoxifen, particularly in patients with desmoid tumors. Copyright:
Authors: Matthew P Goetz; Stacey K Knox; Vera J Suman; James M Rae; Stephanie L Safgren; Matthew M Ames; Daniel W Visscher; Carol Reynolds; Fergus J Couch; Wilma L Lingle; Richard M Weinshilboum; Emily G Barr Fritcher; Andrea M Nibbe; Zeruesenay Desta; Anne Nguyen; David A Flockhart; Edith A Perez; James N Ingle Journal: Breast Cancer Res Treat Date: 2006-11-18 Impact factor: 4.872
Authors: Young Chai Lim; Lang Li; Zeruesenay Desta; Qianqian Zhao; James M Rae; David A Flockhart; Todd C Skaar Journal: J Pharmacol Exp Ther Date: 2006-05-11 Impact factor: 4.030
Authors: Gabriel A C Santos; Isabela W Cunha; Rafael M Rocha; Celso A L Mello; Gustavo C Guimarães; José H Fregnani; Ademar Lopes Journal: Biosci Trends Date: 2010-02 Impact factor: 2.400
Authors: Daniel L Hertz; Allison Deal; Joseph G Ibrahim; Christine M Walko; Karen E Weck; Steven Anderson; Gustav Magrinat; Oludamilola Olajide; Susan Moore; Rachel Raab; Daniel R Carrizosa; Steven Corso; Garry Schwartz; Mark Graham; Jeffrey M Peppercorn; David R Jones; Zeruesenay Desta; David A Flockhart; James P Evans; Howard L McLeod; Lisa A Carey; William J Irvin Journal: Oncologist Date: 2016-05-25
Authors: Werner Schroth; Matthew P Goetz; Ute Hamann; Peter A Fasching; Marcus Schmidt; Stefan Winter; Peter Fritz; Wolfgang Simon; Vera J Suman; Matthew M Ames; Stephanie L Safgren; Mary J Kuffel; Hans Ulrich Ulmer; Julia Boländer; Reiner Strick; Matthias W Beckmann; Heinz Koelbl; Richard M Weinshilboum; James N Ingle; Michel Eichelbaum; Matthias Schwab; Hiltrud Brauch Journal: JAMA Date: 2009-10-07 Impact factor: 56.272
Authors: Joel M Reid; Matthew P Goetz; Sarah A Buhrow; Chad Walden; Stephanie L Safgren; Mary J Kuffel; Kathryn E Reinicke; Vera Suman; Paul Haluska; Xiaonan Hou; Matthew M Ames Journal: Cancer Chemother Pharmacol Date: 2014-10-16 Impact factor: 3.288
Authors: Ernst A Lien; Håvard Søiland; Steinar Lundgren; Turid Aas; Vidar M Steen; Gunnar Mellgren; Jennifer Gjerde Journal: Breast Cancer Res Treat Date: 2013-09-01 Impact factor: 4.872
Authors: Matthew P Goetz; Vera J Suman; Joel M Reid; Don W Northfelt; Michael A Mahr; Andrew T Ralya; Mary Kuffel; Sarah A Buhrow; Stephanie L Safgren; Renee M McGovern; John Black; Travis Dockter; Tufia Haddad; Charles Erlichman; Alex A Adjei; Dan Visscher; Zachary R Chalmers; Garrett Frampton; Benjamin R Kipp; Minetta C Liu; John R Hawse; James H Doroshow; Jerry M Collins; Howard Streicher; Matthew M Ames; James N Ingle Journal: J Clin Oncol Date: 2017-08-30 Impact factor: 50.717
Authors: Emily J Koubek; Andrew T Ralya; Thomas R Larson; Renee M McGovern; Sarah A Buhrow; Joseph M Covey; Alex A Adjei; Naoko Takebe; Matthew M Ames; Matthew P Goetz; Joel M Reid Journal: J Clin Pharmacol Date: 2022-04-19 Impact factor: 2.860